If PER is well advanced in partnership discussions in relation to ATL1102 in DMD then what do they hope to achieve at the BIO International Convention? Of course, no deal is done until its signed and the shortlist may be lengthened and of course no deal may ever be done but maybe the partnering event is to capitalise on other opportunities.
Could the clue be found in yesterday's post by
@Vinceanna and the discussion around the 9 month toxicology study and the unlocking of the most important market for ATL1102 not only in DMD but for other indications. Personally, I was struck by another comment that I pencilled down from the aforementioned Just Stocks interview;
- that data will open a lot of doors for us
The question is what doors? There is another advantage in expediting the DMD deal and that is that it allows management to move onto explore the pipeline in a drug. Is BIO the right opportunity?
